Rajesh Krishna

Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies

Rajesh Krishna, Matt S. Anderson, Arthur Bergman et al. · The Lancet · 2007 · 277 citations

Life Sciences, Pharmacology, Pharmacotherapy +15

Efficacy and Safety of Intranasal Peptide YY3–36 for Weight Reduction in Obese Adults

Ira Gantz, Ngozi Erondu, Madhuja Mallick et al. · The Journal of Clinical Endocrinology & Metabolism · 2007 · 162 citations · Full text

Agriculture, Nutritional Sciences, Pharmacology +17

Multiple-Dose Pharmacodynamics and Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects

Rajesh Krishna, AJ Bergman, Bo Jin et al. · Clinical Pharmacology & Therapeutics · 2008 · 100 citations

Life Sciences, Pharmacokinetics, Pharmacology +16

Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase‐4 inhibitor, in healthy volunteers

Arthur Bergman, David L. Ebel, Fang Liu et al. · Biopharmaceutics & Drug Disposition · 2007 · 89 citations

Pharmacy, Pharmacokinetics, Pharmacology +14

Potent and Selective Agonism of the Melanocortin Receptor 4 With MK-0493 Does Not Induce Weight Loss in Obese Human Subjects: Energy Intake Predicts Lack of Weight Loss Efficacy

Rajesh Krishna, Barry Gumbiner, C. Melinda Stevens et al. · Clinical Pharmacology & Therapeutics · 2009 · 87 citations

Medicine, Endocrinology, Pharmacology +17